Acorda Therapeutics, Inc. (NASDAQ:ACOR)

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

luv2b ;)!

biomedical firm promisses long term result

Big jump is too big. I'll watch it come down

Good stock to have right now.

This stock has been stuck into a classic pattern for the year. We're heading back into the upper $20's this summer. A recession at home isn't going to scare anyone into selling this gem.

Once they get Phamberine XR approved by the FDA the stock will shine, if not... well it's pretty much the end, they can't stay afloat with zanflax especially with all the debt they are using for research into XR.

going back to $16

Go Beta

Assetmangler

One of the two clinical trials required for approval of MS drug has been completed with statistically significant results, which was the reason for the stock runup. Company started 2nd trial already which should be completed in a year or so. There are no other drugs for the MS condition this drug targets, no other clinical trials.

Biotech company in phase III of new drug for MS. More on the way for stroke, head injury. Current widely used Zanaflex sales keeps downside minimal. Expect to be a big winner within year.

Trading at 352% intrinsic value.

speculation?

Its been going up like crazy because of its recent MS drug breakthrough. It will cool off after this passes until the next big drug comes out.

research on therapies for the improvement of neurological functions in people with multiple sclerosis, spinal cord injury, and other disorders of the central nervous system looks very promissing

Optimistic outlook for new MS drug fampridine

I am not very knowledgable about ACORDA, but I know that it sounds too good to be true!!!

sat on my hands and watched it go from 2 to 4 to 11 to 17 bucks before getting on board...all within 3 weeks